

Nicotinamide Riboside for the Prevention and Treatment of Hearing Loss

Lead Inventor:

Samie R. Jaffrey, M.D., Ph.D.

Greenberg-Starr Professor of Pharmacology, Weill Cornell Medical College

Anthony A. Sauve, Ph.D.

Associate Professor of Pharmacology, Weill Cornell Medical College



Business Development Contact:

Lukasz Kowalik Senior Licensing and Business Development Officer (646) 962-7052 kowalik@cornell.edu

Nicotinamide Riboside for the Prevention and Treatment of Hearing Loss

Background & Unmet Need

- Noise exposure is a major cause of hearing loss, which lacks effective treatment or prophylaxis
- Following noise exposure, hair cells release neurotransmitters that lead to excitotoxic damage to the neurites, resulting in synaptic disruption and neurite retraction
- Nicotinamide adenine dinucleotide (NAD+) exhibits axon-protective effects in cultured neurons, but its ability to block degeneration in vivo is confounded by poor cell permeability and serum instability
- Unmet Need: Novel neuroprotective therapeutics that prevent against hearing loss after noise exposure

Technology Overview

- The Technology: Method of preventing and treating hearing loss by administering agents that increase intracellular NAD+ levels
- **Discovery:** Augmentation of intracochlear NAD+ levels protects mice from noise-induced hearing loss (NIHL)
- Administration of nicotinamide riboside (NR) provides an efficient route to increase NAD+ levels in the cochlea in mice and protects from NIHL
- NR also prevented retraction of spiral ganglia neurites from the inner hair cells, demonstrated that NR activates a NAD+-SIRT3 pathway that reduces neurite degeneration caused by noise exposure

Inventors:

Samie R. Jaffrey Anthony A. Sauve Kevin Brown

Patents: US Patent 9,861,651

Publications: Brown et al. Cell Metabolism. 2014.

Biz Dev Contact: Lukasz Kowalik (646) 962-7052 kowalik@cornell.edu

Cornell Reference: D-5990

Nicotinamide Riboside for the Prevention and Treatment of Hearing Loss

Technology Applications

- Therapeutic agents for preventing and treating hearing loss
- Method to determine if a compound acts as a hearing protective agent



- Nicotinamide riboside, an NAD+ precursor, overcomes the cell permeability and serum instability challenges of directly administering NAD+
- May be given prophylactically to patients at high risk of hearing loss (e.g., musicians, construction workers)




Figure 2: Activation of SIRT3 by the NAD+ precursor nicotinamide riboside prevents neurite retraction from the inner hair cells in a SIRT3-dependent manner.

Inventors:

Samie R. Jaffrey Anthony A. Sauve Kevin Brown

Patents:

US Patent 9,861,651

Publications:

Brown et al. Cell Metabolism. 2014.

Biz Dev Contact: Lukasz Kowalik (646) 962-7052 kowalik@cornell.edu

Cornell Reference: D-5990



Weill Cornell Medicine